The use of psychedelic agents with autistic schizophrenic children

Earlier exploratory work examined administering psychedelic agents to young children with severe psychological disturbance, but the reports are fragmentary, heterogeneous, and often unpublished. Mogar and colleagues note wide diversity across those early studies in the drug used, dose and dosing schedule, therapist experience and expectations, and the physical and psychological setting of administration. Patient samples also varied in age and symptom profile, and most investigations suffered from small sizes, subjective outcome criteria, and poor follow-up, factors that together have limited the field’s uptake and produced polarized controversy that curtailed publicly sanctioned research. This paper reviews and integrates seven independent studies in which psychedelic drugs were given to children diagnosed with autism or childhood schizophrenia. The stated aim is heuristic rather than conclusive: to summarise commonalities and differences across studies, identify likely determinants of inconsistent findings, and indicate directions for more definitive future research into the therapeutic potential of psychedelics in childhood disorders.

Mogar and colleagues conducted a literature review of seven clinical and research reports that collectively involved 91 children treated with psychedelic agents for therapeutic or experimental purposes. The extracted text indicates a ‘‘fairly exhaustive’’ search but does not detail databases, search dates, or formal inclusion criteria. The reviewed reports span varied designs and methods rather than a single standardised protocol. The pooled sample ranged from five to fifteen years of age, with most children between six and ten. All patients were described as severely and chronically disturbed, with primary diagnoses of autism or childhood schizophrenia; many had been hospitalised for two to four years and a majority were long-standing mute prior to treatment. Individual study designs varied widely: some investigators (Rolo, Simmons) used double-blind procedures to introduce experimental control, while others (Bender, Fisher and Castile) employed open therapeutic approaches. Dosage practices differed considerably. Most investigators reportedly considered 100 micrograms (μg) of LSD as typical; Bender started at 50 μg and titrated up to 150 μg, whereas Fisher and Castile used a broad LSD range of 50–400 μg and sometimes combined agents (LSD and psilocybin, occasionally simultaneously). Fisher and Castile also described a regime including pre-medication with 10 mg Librium, 10–15 mg psilocybin given about 30 minutes later, and then 250–300 μg LSD, with possible session “boosters” of 25–100 μg. Investigators differed in the therapeutic milieu and therapist role. Fisher and Castile attempted a deliberately non-medical, extended-session approach modelled on contemporary techniques (7–10 hour sessions, music, meaningful objects, a male and female therapist experienced with psychedelics, active role-playing). By contrast, Freedman’s orientation was primarily psychotomimetic observation with limited therapist engagement, and Bender often administered LSD as a routine daily medication without special preparatory conditions. Rolo and Simmons standardised sessions with play tasks or structured games to elicit social behaviours. Outcome assessment was mainly observational during acute drug effects; formal pre–post baselines and systematic follow-up were generally lacking, with the exception of Bender who administered the Vineland Maturity Scale at baseline and at a three-month follow-up in one study. The extracted text does not report statistical analysis methods or meta-analytic techniques, consistent with a narrative synthesis rather than quantitative pooling.

Across the seven reports covering 91 children, the most consistently reported effects were: improved speech behaviour in previously mute patients, increased emotional responsiveness toward peers and adults, elevated positive mood (including frequent laughter), and reductions in compulsive, ritualistic behaviours. These patterns appear repeatedly in the case descriptions despite methodological heterogeneity. Patient characteristics described in the reports included a predominance of severe, chronic disturbance with long-standing mutism in nearly all 91 children. Illness duration varied; most had been hospitalised for two to four years, while Fisher and Castile’s subgroup (N = 12) averaged 7.6 years of illness. The investigators did not find clear evidence that age, diagnosis (autism versus childhood schizophrenia), or illness duration consistently predicted response, although some authors (Fisher and Castile, Bender) suggested tentative relationships in their more detailed assessments. Drug regimens produced varied exposures: psilocybin and LSD were used singly and together; typical LSD dosing centred on 100 μg but ranged up to 400 μg in some protocols, with reported strategies including titration, pre-medication, and intra-session boosters. Only a minority of studies attempted experimental controls: Rolo and Simmons used double-blind methods with standardised tasks, while Freedman’s study involved single-session observation and Bender reported repeated daily dosing over extended periods (up to a year in some accounts). Objective measurement was scarce. Most data were observational during acute drug reactions and pretreatment baselines and systematic follow-up were generally absent. One exception was Bender’s use of the Vineland Maturity Scale, where follow-up ratings at three months were described as qualitatively higher for all children assessed. The extracted text does not provide aggregate numerical effect sizes, confidence intervals, p-values, or systematic adverse-event counts. Authors repeatedly attribute variability in outcomes to differences in drug regime, therapist expectations and experience, and the physical/psychological milieu in which sessions occurred.

Mogar and colleagues interpret the collective literature cautiously, emphasising that the psychedelic experience is embedded within a broader psychosocial process and that drug effects cannot be meaningfully separated from therapist–patient interactions, setting, and investigator expectations. They argue that more favourable therapeutic outcomes were associated with active therapist involvement, congenial non-medical settings offering meaningful sensory and interpersonal stimuli, and flexible approaches that allowed spontaneous behaviour. Conversely, sterile medical or laboratory environments and mechanically administered procedures appeared to be counter-therapeutic in these reports. The authors underscore substantive limitations in the evidence base: small and heterogeneous samples, largely observational outcome reporting, vague or subjective improvement criteria, variable and sometimes extreme dosing strategies, infrequent use of blinding or controls, and inadequate follow-up. They also note the lack of explicit theoretical rationale in many studies, though several investigators hypothesised that psychedelics might disrupt defensive structures in childhood psychosis and thereby facilitate contact and communication. Mogar and colleagues present the reviewed work as heuristic: despite its shortcomings, the consistency of certain clinical observations (speech gains, emotional responsiveness, mood elevation, reduction of ritualistic behaviour) across disparate reports warrants more rigorous replication. They recommend more definitive studies that control for non-drug determinants of outcome, standardise dosing and therapeutic milieu, employ objective pre–post measurement and longer follow-up, and use appropriate experimental controls. The extracted text emphasises that broader social controversy over psychedelics has restricted public research funding and dissemination, a context that has contributed to the fragmentary nature of the literature.